Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Memory modulation with peripherally acting cholinergic drugs.

D K Rush1, K Streit

  • 1Cassella AG, Department of CNS Pharmacology, Frankfurt, Federal Republic of Germany.

Psychopharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.

The Journal of pharmacology and experimental therapeutics·1997
Same author

Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

The Journal of pharmacology and experimental therapeutics·1996
Same author

Effects of chronic intrahippocampal infusion of lipopolysaccharide in the rat.

Neuroscience·1996
Same author

The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.

The Journal of pharmacology and experimental therapeutics·1995
Same author

Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.

Journal of medicinal chemistry·1995
Same author

Velnacrine maleate improves delayed matching performance by aged monkeys.

Psychopharmacology·1995
Same journal

GlyT1 inhibition enhances working memory in the mouse TUNL task and normalizes NMDA antagonist-induced network activity.

Psychopharmacology·2026
Same journal

Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

Psychopharmacology·2026
Same journal

Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

Psychopharmacology·2026
Same journal

Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

Psychopharmacology·2026
Same journal

Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

Psychopharmacology·2026
Same journal

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Psychopharmacology·2026
See all related articles

Physostigmine and neostigmine reversed scopolamine-induced amnesia in mice. This memory recovery involved peripheral muscarinic and nicotinic receptors, potentially via adrenal catecholamines.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Science

Background:

  • Scopolamine is known to induce amnesia by disrupting cholinergic systems.
  • Acetylcholinesterase inhibitors are investigated for their potential to counteract memory deficits.
  • Understanding the receptor mechanisms underlying amnesia and its reversal is crucial for cognitive enhancement.

Purpose of the Study:

  • To investigate the efficacy of physostigmine and neostigmine in antagonizing scopolamine-induced amnesia.
  • To elucidate the specific receptor pathways (muscarinic and nicotinic) involved in the reversal of amnesia.
  • To explore the potential role of peripheral systems in memory modulation.

Main Methods:

  • Administered scopolamine to induce amnesia in a step-through passive avoidance task in mice.

Related Experiment Videos

  • Tested the effects of physostigmine and neostigmine, acetylcholinesterase inhibitors, on reversing scopolamine-induced amnesia.
  • Utilized specific muscarinic and nicotinic antagonists (mecamylamine, hexamethonium) to probe receptor involvement.

    • Main Results:

    • Physostigmine and neostigmine effectively antagonized scopolamine-induced amnesia.
    • Neostigmine's reversal effect was attenuated by both central/peripheral and peripheral-only antagonists, suggesting peripheral mediation.
    • Central administration of scopolamine and mecamylamine alone induced amnesia, highlighting the role of central cholinergic systems.

    Conclusions:

    • Amnesia induction involves central cholinergic pathways.
    • Reversal of scopolamine-induced amnesia by neostigmine and possibly physostigmine is mediated by peripheral muscarinic and nicotinic receptors.
    • Adrenal catecholamine release and subsequent glucose influence may underlie the observed memory antagonism.